# Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children

> **NCT02484261** · PHASE1 · TERMINATED · sponsor: **Reuven Schore** · enrollment: 10 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Pravastatin

## Key facts

- **NCT ID:** NCT02484261
- **Lead sponsor:** Reuven Schore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2018-05-18
- **Final completion:** —
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Contractual/Funding/Accrual
- **Last updated:** 2023-03-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02484261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02484261, "Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02484261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*